What Building In-House gets wrong in Healthcare
Building pharmaceutical technology in-house requires a combination of GxP validation expertise, FDA 21 CFR Part 11 architectural knowledge, and software engineering skills that is rare in the labor market. Most pharmaceutical companies attempting to build validated systems in-house discover the gap between 'engineer who has read Part 11' and 'engineer who has built a validated system that survived an FDA inspection' when the 483 observation arrives.
GxP validation is not a process that can be learned by doing it once under pressure. The GAMP 5 framework, the validation lifecycle, the change control documentation requirements, and the audit trail architecture that survives ALCOA+ review — these are disciplines developed over multiple validation cycles. An in-house team building its first validated system will make architectural decisions that experienced validation engineers know to avoid.
Clinical data management, manufacturing execution systems, and laboratory information management systems all have FDA inspection risk that in-house teams underestimate at the outset. A validated system with architecture gaps is not better than no system — it is worse, because it produces false confidence in an audit that identifies the gaps.
What we deploy instead
We provide the GxP-validated pharmaceutical technology team that in-house recruiting cannot assemble at the speed that clinical timelines require. Validation engineers with FDA inspection experience. Part 11-compliant architectures built from the first data model.
Validation documentation generated as part of the build — not assembled retrospectively. Your team owns and maintains the validated system after close.
FDA 21 CFR PART 11 and HIPAA built into the architecture from day one — enforced automatically by ALICE at every commit.
Fixed-price engagements. Production system in 8-20 weeks. No discovery phase. No change orders.
Domain-qualified engineers with healthcare experience. The senior engineer who scopes the engagement is the senior engineer who delivers it.
Full source code and documentation transferred at close. No licensing. No managed services dependency.
The compliance difference
FDA 21 CFR Part 11, GAMP 5, GxP validation. In-house pharmaceutical technology development without validation expertise produces compliance risk that surfaces at FDA inspection. We build systems that are ready for inspection from day one.
What switching from Building In-House looks like
Pharmaceutical technology engagement: 14-22 weeks for a GxP-validated production system. Team: 8-14 engineers, 1 validation specialist. Fixed price. Full validation documentation at close.
Architecture review and scope definition. We review existing deliverables and identify gaps.
Scope locked, team assembled, first sprint underway. Working code from week two.
First production milestone — a working integration or system component, not a document.
Full IP transfer. Source code, documentation, operational runbooks. Your team runs the system.
Failed Vendor Recovery Playbook
Step-by-step framework for recovering from a failed Building In-House engagement — from emergency stabilisation through full re-platforming. 4-phase playbook covering stabilise, assess, transition, and normalise.